The collaboration targets the growing need for large-volume subcutaneous drug delivery, driven by the shift to complex biologics and patient preference for self-administration. Advances in device ...
Enables convenient on-body delivery of higher dose therapies like anti-cancer treatments and monoclonal antibodies Utilizes a pre-verified large-volume platform solution to speed time to market Meets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results